ReviewOncoTargets and therapy2026
The Role of DNA Methylation in Osteosarcoma Pathogenesis and Therapy.
Review in OncoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS) is a highly malignant bone tumor primarily affecting children and adolescents. Clinical treatment has consistently encountered challenges, including chemotherapy resistance, high recurrence rates, and metastasis. Research has demonstrated that epigenetic regulation, particularly DNA methylation, can stably modify the DNA sequence without altering it, playing a key role in the development and progression of OS. Compared with normal tissue, OS exhibits distinctive alterations in DNA methylation, characterized by genome-wide hypomethylation and hypermethylation of specific gene promoter regions. This "dual pattern" not only promotes tumor proliferation, invasion, and metastasis but also maintains cancer stem cell characteristics and modulates the tumor immune microenvironment (TIME). Molecular classification based on DNA methylation profiles offers a new tool for the diagnosis and prognosis of OS. Drugs targeting DNA methylation, such as decitabine, have shown promising results for reversing gene silencing and suppressing tumor progression. This article systematically reviews the core mechanisms by which DNA methylation contributes to OS development, progression, and metastasis, and examines its potential for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.